We are live on
!
Find out more
VCG
Vantage Consulting Group Portfolio holdings
AUM
$19.7M
1-Year Est. Return
280.87%
This Fund
S&P 500
This Quarter
Est. Return
+17.65%
1 Year Est. Return
+280.87%
3 Year Est. Return
+261.08%
5 Year Est. Return
+180.34%
10 Year Est. Return
–
AUM
$1.23B
AUM Growth
–
Cap. Flow
+$1.06B
Cap. Flow
% of AUM
86.51%
Top 10 Holdings %
Top 10 Hldgs %
94.5%
Holding
1,884
New
1,883
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$911M |
| 2 |
ADC Therapeutics
ADCT
|
+$55.1M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$25.5M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$5.96M |
| 5 |
Kroger
KR
|
+$366K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.04% |
| 2 | Technology | 0.89% |
| 3 | Consumer Discretionary | 0.79% |
| 4 | Industrials | 0.61% |
| 5 | Consumer Staples | 0.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
General Dynamics
GD
$103B
| $79K | 0.01% |
+529
| New | +$77.3K |
|
252
MetLife
MET
$62B
| $79K | 0.01% |
+1,680
| New | +$72.8K |
|
253
PACCAR
PCAR
$69.5B
| $79K | 0.01% |
+1,377
| New | +$80.9K |
|
254
Prudential Financial
PRU
$42.7B
| $79K | 0.01% |
+1,007
| New | +$72.8K |
|
255
Aflac
AFL
$64.5B
| $78K | 0.01% |
+1,765
| New | +$72.3K |
|
256
Applied Materials
AMAT
$434B
| $78K | 0.01% |
+902
| New | +$66.7K |
|
257
Halliburton
HAL
$26.6B
| $78K | 0.01% |
+4,125
| New | +$64K |
|
258
Incyte
INCY
$24B
| $78K | 0.01% |
+897
| New | +$77.6K |
|
259
Lincoln National
LNC
$8.82B
| $78K | 0.01% |
+1,543
| New | +$65.6K |
|
260
SLB Ltd
SLB
$73.2B
| $78K | 0.01% |
+3,557
| New | +$67.1K |
|
261
Tactile Systems Technology
TCMD
$672M
| $78K | 0.01% |
+1,726
| New | +$68.6K |
|
262
Thermo Fisher Scientific
TMO
$212B
| $78K | 0.01% |
+167
| New | +$78.3K |
|
263
Unum
UNM
$14.3B
| $78K | 0.01% |
+3,408
| New | +$70.5K |
|
264
CEVA Inc
CEVA
$927M
| $77K | 0.01% |
+1,693
| New | +$69.5K |
|
265
Huntington Ingalls Industries
HII
$12.8B
| $77K | 0.01% |
+450
| New | +$71.5K |
|
266
Inogen
INGN
$182M
| $77K | 0.01% |
+1,716
| New | +$59.2K |
|
267
Eli Lilly
LLY
$995B
| $77K | 0.01% |
+458
| New | +$68.4K |
|
268
Lockheed Martin
LMT
$135B
| $77K | 0.01% |
+218
| New | +$80.1K |
|
269
Revvity
RVTY
$12.4B
| $77K | 0.01% |
+536
| New | +$71.3K |
|
270
Lam Research
LRCX
$398B
| $76K | 0.01% |
+1,610
| New | +$67.7K |
|
271
Vertex Pharmaceuticals
VRTX
$119B
| $76K | 0.01% |
+322
| New | +$73.9K |
|
272
Alaska Air
ALK
$5.6B
| $75K | 0.01% |
+1,437
| New | +$64.6K |
|
273
Boeing
BA
$187B
| $75K | 0.01% |
+349
| New | +$67.1K |
|
274
TechnipFMC
FTI
$27.1B
| $75K | 0.01% |
+10,779
| New | +$63.4K |
|
275
Dorian LPG
LPG
$1.97B
| $75K | 0.01% |
+6,157
| New | +$60.9K |
|
Similar funds
MVG
NCM
FFGIM
PIM
HFG
SWM
ICM
SM
Vantage Consulting Group's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for Vantage Consulting Group, which disclosed 1,884 positions worth $1.23B. Its ten largest holdings account for 94% of the portfolio.
Its largest position is Royalty Pharma: 21,477,282 shares worth $1.07B.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, followed by Technology and Consumer Discretionary.
- Vantage Consulting Group's largest Q4 2020 buy was Royalty Pharma: 21,477,282 shares worth $1.07B.
- Vantage Consulting Group's ten largest holdings make up 94% of its $1.23B portfolio in Q4 2020.
- Vantage Consulting Group disclosed 1,884 positions in Q4 2020, its first 13F filing on record.
Based on Vantage Consulting Group's 13F filing for Q4 2020, filed 12 Feb 2021.